Clinical trial
A Phase I Study of Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant
NCT02477878 is registered in ClinicalTrials.gov with Bellicum Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant
- Lead sponsor
- Bellicum Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- July 31, 2016
- Completion date
- January 31, 2033
- Enrollment
- 10 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.